- Trial phase
- Phase 3
- Time to market
- Years away if at all. The drug is still investigational with no FDA filing. The ongoing Phase 3 SigVie-003 (frontline combination) is still recruiting; even if positive, a regulatory submission would be at least 1-2 years away.
- Why 3/10
- The drug's pivotal Phase 3 SigVie-002 readout (June 22, 2026) has already occurred and was a miss. There is no pending PDUFA or regulatory decision. The next hard catalyst would be a topline readout from the ongoing Phase 3 SigVie-003 (frontline combination), but that trial is still recruiting with no disclosed timeline. At a diversified mega-cap like Pfizer (~$170B market cap), even a successful readout would not drive a dominant share-price move, placing this at a low impact score.
The next catalyst for sigvotatug vedotin is the ongoing Phase 3 SigVie-003 readout (frontline combination with pembrolizumab in PD-L1-high NSCLC), but that trial is still recruiting with no publicly disclosed topline timeline. Pfizer management indicated continued investment in the lung cancer program despite the SigVie-002 miss. Watch for enrollment completion updates or interim analysis announcements from Pfizer.
Price Chart
Executive Summary
Sigvotatug vedotin is an investigational antibody-drug conjugate (ADC) targeting integrin beta-6, originally developed by Seagen and now owned by Pfizer following the $43 billion acquisition in December 2023. Its pivotal Phase 3 SigVie-002 trial in 703 patients with previously treated non-squamous non-small cell lung cancer (NSCLC) failed to improve overall survival versus docetaxel, announced June 22, 2026. Pfizer is continuing development with an ongoing Phase 3 SigVie-003 trial testing the drug in combination with pembrolizumab as first-line therapy in PD-L1-high NSCLC, plus other combination studies. For a diversified mega-cap like Pfizer, this single pipeline setback is manageable but represents a blow to the Seagen ADC thesis.
How It Works
Sigvotatug vedotin is an antibody-drug conjugate (ADC), a type of targeted cancer therapy. It works like a guided missile: one part is an antibody that seeks out and binds to a protein called integrin beta-6 (IB6), which is found on the surface of about 90% of non-small cell lung cancer tumors but less so on normal cells. Once bound, the drug releases a chemotherapy-like toxin (MMAE) directly inside the cancer cell, killing it. The 'vedotin' part refers to the specific linker and toxin technology originally developed by Seagen.
Trial Status
The Phase 3 SigVie-002 trial (sigvotatug vedotin vs docetaxel in 2L+ non-squamous NSCLC, n=703) failed to meet its primary overall survival endpoint, announced June 22, 2026. Data were presented at ESMO 2026 (October 2026). A post-hoc analysis showed a numerical OS trend in second-line patients. The Phase 3 SigVie-003 trial (sigvotatug vedotin + pembrolizumab vs pembrolizumab alone as first-line therapy in PD-L1-high NSCLC) is ongoing and recruiting. Additional combination studies with a PD-1/VEGF bispecific antibody are also underway.
The Two-Sided Case
Upcoming Catalysts
- Topline readout from Phase 3 SigVie-003 (frontline sigvotatug vedotin + pembrolizumab in PD-L1-high NSCLC) - no date disclosed, trial still recruiting
- Potential interim data or updates from combination studies with PF-4404 (PD-1/VEGF bispecific)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
PFIZER INC 8-K PFE ·Originating report